Curated News
By: NewsRamp Editorial Staff
June 04, 2025

Soligenix's HyBryte Shows Promise in CTCL Treatment

Reddit Discuss on LinkedIn Discuss on Substack participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Soligenix's HyBryte(TM) shows a 75% success rate in early-stage CTCL treatment, offering a competitive edge in biopharmaceutical innovations for rare diseases.
  • HyBryte(TM) treatment for CTCL demonstrated 75% efficacy at 18 weeks, with safety and tolerability confirmed in an ongoing open-label study mirroring the FLASH2 trial design.
  • HyBryte(TM) provides a safer, faster-acting treatment for CTCL, improving patient outcomes and addressing the urgent need for new therapies in this underserved area.
  • Discover how Soligenix's HyBryte(TM) is revolutionizing CTCL treatment with an 85% improvement rate, offering hope through its non-mutagenic mechanism and rapid response.

Impact - Why it Matters

This news is significant for patients suffering from early-stage cutaneous T-cell lymphoma (CTCL) and the broader medical community. HyBryte(TM) represents a potentially safer, more effective treatment option compared to existing therapies, which often come with severe side effects. The success of this treatment could revolutionize the approach to managing CTCL, offering patients a better quality of life and hope for long-term remission. Additionally, Soligenix's work in developing treatments for other rare diseases and vaccines underscores the company's role in addressing critical health challenges, making this news relevant not just to CTCL patients but to anyone interested in advancements in medical science and public health.

Summary

Soligenix (SNGX) is making waves in the biopharmaceutical industry with its latest interim data on HyBryte(TM), a promising treatment for early-stage cutaneous T-cell lymphoma (CTCL). Highlighted in a podcast by the Cutaneous Lymphoma Foundation, Dr. Ellen Kim shared encouraging results, including a 75% treatment success rate at 18 weeks and up to 85% improvement in patients treated through 54 weeks. The study, which builds on the Phase 3 FLASH trial, emphasizes HyBryte's safety and tolerability, marking it as a potential game-changer for CTCL patients. The open-label study's design, mirroring real-world clinical practice, has shown enhanced efficacy without serious side effects, offering a beacon of hope for those battling this chronic cancer.

Beyond CTCL, Soligenix is broadening its horizons with HyBryte's application in psoriasis and developing other innovative treatments, including vaccines for ricin toxin, filoviruses, and COVID-19. Supported by government grants, Soligenix's Public Health Solutions business segment is at the forefront of addressing unmet medical needs with its proprietary technologies. For more insights into Soligenix's groundbreaking work and to listen to the podcast, visit https://ibn.fm/sCfYo and explore the company's website at www.Soligenix.com.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix's HyBryte Shows Promise in CTCL Treatment

blockchain registration record for this content.